ANKRD22 promotes progression of non-small cell lung cancer through transcriptional up-regulation of E2F1

Abstract Lung cancer is the leading cause of death among all malignancies due to rapid tumor progression and relapse; however, the underlying molecular mechanisms of tumor progression are unclear. In the present study, we identified ANKRD22 as a novel tumor-associated gene in non-small cell lung can...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Jun Yin, Wenfan Fu, Lu Dai, Zeyong Jiang, Hongying Liao, Wenbin Chen, Lei Pan, Jian Zhao
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2017
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/7ebadbcc5ad54b848f15fd48911779e1
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:7ebadbcc5ad54b848f15fd48911779e1
record_format	dspace
spelling	oai:doaj.org-article:7ebadbcc5ad54b848f15fd48911779e12021-12-02T16:07:47ZANKRD22 promotes progression of non-small cell lung cancer through transcriptional up-regulation of E2F110.1038/s41598-017-04818-y2045-2322https://doaj.org/article/7ebadbcc5ad54b848f15fd48911779e12017-06-01T00:00:00Zhttps://doi.org/10.1038/s41598-017-04818-yhttps://doaj.org/toc/2045-2322Abstract Lung cancer is the leading cause of death among all malignancies due to rapid tumor progression and relapse; however, the underlying molecular mechanisms of tumor progression are unclear. In the present study, we identified ANKRD22 as a novel tumor-associated gene in non-small cell lung cancer (NSCLC). According to the clinical correlation analysis, ANKRD22 was highly expressed in primary cancerous tissue compared with adjacent cancerous tissue, and high expression levels of ANKRD22 were significantly correlated with relapse and short overall survival time. Knockdown and overexpression analysis revealed that ANKRD22 promoted tumor progression by increasing cell proliferation. In xenograft assays, knockdown of ANKRD22 or in vivo treatment with ANKRD22 siRNA inhibited tumor growth. Furthermore, ANKRD22 was shown to participate in the transcriptional regulation of E2F1, and ANKRD22 promoted cell proliferation by up-regulating the expression of E2F1 which enhanced cell cycle progression. Therefore, our studies indicated that ANKRD22 up-regulated the transcription of E2F1 and promoted the progression of NSCLC by enhancing cell proliferation. These findings suggest that ANKRD22 could potentially act as a novel therapeutic target for NSCLC.Jun YinWenfan FuLu DaiZeyong JiangHongying LiaoWenbin ChenLei PanJian ZhaoNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 7, Iss 1, Pp 1-11 (2017)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Jun Yin Wenfan Fu Lu Dai Zeyong Jiang Hongying Liao Wenbin Chen Lei Pan Jian Zhao ANKRD22 promotes progression of non-small cell lung cancer through transcriptional up-regulation of E2F1
description	Abstract Lung cancer is the leading cause of death among all malignancies due to rapid tumor progression and relapse; however, the underlying molecular mechanisms of tumor progression are unclear. In the present study, we identified ANKRD22 as a novel tumor-associated gene in non-small cell lung cancer (NSCLC). According to the clinical correlation analysis, ANKRD22 was highly expressed in primary cancerous tissue compared with adjacent cancerous tissue, and high expression levels of ANKRD22 were significantly correlated with relapse and short overall survival time. Knockdown and overexpression analysis revealed that ANKRD22 promoted tumor progression by increasing cell proliferation. In xenograft assays, knockdown of ANKRD22 or in vivo treatment with ANKRD22 siRNA inhibited tumor growth. Furthermore, ANKRD22 was shown to participate in the transcriptional regulation of E2F1, and ANKRD22 promoted cell proliferation by up-regulating the expression of E2F1 which enhanced cell cycle progression. Therefore, our studies indicated that ANKRD22 up-regulated the transcription of E2F1 and promoted the progression of NSCLC by enhancing cell proliferation. These findings suggest that ANKRD22 could potentially act as a novel therapeutic target for NSCLC.
format	article
author	Jun Yin Wenfan Fu Lu Dai Zeyong Jiang Hongying Liao Wenbin Chen Lei Pan Jian Zhao
author_facet	Jun Yin Wenfan Fu Lu Dai Zeyong Jiang Hongying Liao Wenbin Chen Lei Pan Jian Zhao
author_sort	Jun Yin
title	ANKRD22 promotes progression of non-small cell lung cancer through transcriptional up-regulation of E2F1
title_short	ANKRD22 promotes progression of non-small cell lung cancer through transcriptional up-regulation of E2F1
title_full	ANKRD22 promotes progression of non-small cell lung cancer through transcriptional up-regulation of E2F1
title_fullStr	ANKRD22 promotes progression of non-small cell lung cancer through transcriptional up-regulation of E2F1
title_full_unstemmed	ANKRD22 promotes progression of non-small cell lung cancer through transcriptional up-regulation of E2F1
title_sort	ankrd22 promotes progression of non-small cell lung cancer through transcriptional up-regulation of e2f1
publisher	Nature Portfolio
publishDate	2017
url	https://doaj.org/article/7ebadbcc5ad54b848f15fd48911779e1
work_keys_str_mv	AT junyin ankrd22promotesprogressionofnonsmallcelllungcancerthroughtranscriptionalupregulationofe2f1 AT wenfanfu ankrd22promotesprogressionofnonsmallcelllungcancerthroughtranscriptionalupregulationofe2f1 AT ludai ankrd22promotesprogressionofnonsmallcelllungcancerthroughtranscriptionalupregulationofe2f1 AT zeyongjiang ankrd22promotesprogressionofnonsmallcelllungcancerthroughtranscriptionalupregulationofe2f1 AT hongyingliao ankrd22promotesprogressionofnonsmallcelllungcancerthroughtranscriptionalupregulationofe2f1 AT wenbinchen ankrd22promotesprogressionofnonsmallcelllungcancerthroughtranscriptionalupregulationofe2f1 AT leipan ankrd22promotesprogressionofnonsmallcelllungcancerthroughtranscriptionalupregulationofe2f1 AT jianzhao ankrd22promotesprogressionofnonsmallcelllungcancerthroughtranscriptionalupregulationofe2f1
_version_	1718384725975891968

ANKRD22 promotes progression of non-small cell lung cancer through transcriptional up-regulation of E2F1

Ejemplares similares